TrialBlood advances2021

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

Ken Ohmachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.